cigna glp-1 Why is capping cost increases for pricey weight loss drugs Good news! Your insurance may

Lillys orforglipron, a once-daily pill, posted Phase 3 wins in T2D and obesity: according to the New England Journal of Medicine, in a head-to-head T2D study, orforglipron cut A1C by 2.2% vs 1.4% for oral semaglutide

Defective mitophagy in aged macrophages promotes mitochondrial DNA cytosolic leakage to activate STING signaling during liver sterile inflammation

FarragYFarragMVarela-GarcaMTorrijos-PulpnCCapuozzoMOttaianoAet al

This supports the absence of biochemical or clinical signs of hypothyroidism in selenium-deficient PKU patients [35]

Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, glucagon) that remains unlicensed in the UK, with no MHRA approval, no NHS availability, and no BNF listing as of 20242025